These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Author: Teichmann A.
    Journal: Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257.
    Abstract:
    The alterations in lipid metabolism that occur with the use of oral contraceptives (OCs) have aroused considerable concern that OCs might increase the risk of premature atherosclerosis. However, most studies examining the role of OCs in atherogenesis were performed using earlier-generation preparations employing larger doses of sex hormones than present formulation. Therefore, we undertook a comparative and standardized determination of the effects on lipid metabolism of six modern, low-dose OCs. This open, randomized, comparative study included patients recruited at 21 study centers throughout Europe. Four hundred sixty-six women, aged 18-38 years, participated. They were randomly assigned to the following OC formulations:(1) norgestimate 250 micrograms + ethinyl estradiol (EE) 35 micrograms (Cilest); (2) norgestimate 180/215/250 micrograms + EE 35 micrograms (Tricilest); (3) desogestrel 150 micrograms + EE 20 micrograms = (Marvelon); (4) desogestrel 150 micrograms + EE 30 micrograms (Mercilon); (5) gestodene 75 micrograms + EE 30 micrograms (Femovan); and (6) gestodene 50/70/100 micrograms + EE 30/40/30 micrograms (Trifemovan). There were three parallel studies with six parallel patient groups. Fasting blood samples were drawn at baseline (between days 24 and 28) and on days 18-22 of cycle 6, and cycle 12. Sample were analyzed for total cholesterol,high-density lipoprotein (HDL) cholesterol, HDL2 cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, apolipoprotein (apo)A1, and apoB at one central laboratory. Two hundred eighty-two women completed all 12 cycles and were included in the final evaluation. As expected, triglyceride and total cholesterol concentrations increased in all study groups but to lesser levels with the formulations containing gestodene. All OCs, except the monophasic gestodene preparation, slightly but significantly increased HDL. The HDL2 subfraction did ot change significantly except in the group using the monophasic gestodene preparation; in this group, the HDL2 subfraction slightly but significantly decreased. The LDL concentration increased slightly with the monophasic and triphasic norgestimate preparations and with desogestrel + 20 micrograms EE. The LDL/HDL ratio did not change significantly except with the use of the triphasic norgestimate preparation, in which case it decreased slightly. ApoA1 and apoB levels increased only slightly with all formulations. Importantly, while all of the OCs tested altered lipid levels to some extent, after 12 cycles there were no statistically significant differences in lipid effects among OC preparations. Modern, combined OCs that contain norgestimate, desogestrel, or gestodene all have some impact on lipid levels. However, it would appear likely that they do not contribute to atherogenesis in healthy women. The changes in lipid metabolism which occur with the use of oral contraceptives (OCs) have prompted concern about the potential for OCs to increase the risk of premature atherosclerosis. Findings are reported from the study of the effects on lipid metabolism of six modern low-dose OCs. 466 women aged 18-38 years recruited from 21 study centers throughout Europe participated. Subjects were randomly assigned to the following OC formulations: norgestimate 250 mcg and 35 mcg ethinyl estradiol (EE), 180/215/250 mcg of norgestimate and 35 mcg EE, 150 mcg desogestrel and 20 mcg EE, 150 mcg desogestrel and 30 mcg EE, 75 mcg gestodene and 30 mcg EE, and 50/70/100 mcg gestodene and 30/40/30 mcg EE. There were three parallel studies with six parallel patient groups. Fasting blood samples were drawn for the analysis of cholesterol, lipoproteins, and triglycerides between days 24 and 28 and on days 18-22 of cycles 6 and 12. 282 women completed all 12 cycles and were included in the final evaluation. Triglyceride and total cholesterol concentrations increased in all study groups, but to lesser levels with the formulations containing gestodene. All OCs, except the monophasic gestodene preparation, slightly but significantly increased high-density lipoprotein (HDL) cholesterol. The HDL(2) cholesterol subfraction slightly, but significantly, decreased among women using the monophasic gestodene preparation. The low-density lipoprotein (LDL) cholesterol concentration increased slightly with the monophasic and triphasic norgestimate preparations and with desogestrel combined with 20 mcg EE. The only significant change, a slight decrease, in the LDL/HDL ratio occurred with the use of the triphasic norgestimate preparation. While all of the OCs tested altered lipid levels, after 12 cycles there were no statistically significant differences in lipid effects among OC preparations. These findings suggest that, although modern combined OCs containing norgestimate, desogestrel, or gestodene all have some impact upon lipid levels, they probably do not contribute to atherogenesis in healthy women.
    [Abstract] [Full Text] [Related] [New Search]